Cerity Partners’s GT Biopharma GTBP Stock Holding History

Cerity Partners’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-801	Closed	-$8.17K	–	3479
2026 Q1	$8.17K	Buy	801 +201	+34%	+$2.74K	﹤0.01%	3218
2025 Q4	$11.8K	Buy	+600	New	+$10.7K	﹤0.01%	2858

Other funds holding GTBP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

Opal Wealth Advisors Jericho, New York $479M AUM 15.43% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return

Alongside Austin, Texas $525M AUM

Cerity Partners's GTBP Position: Q2 2026 in Review

Cerity Partners sold out of GT Biopharma (GTBP) in Q2 2026, closing a stake of 801 shares — an estimated $8.17K sold.

Cerity Partners first reported a position in GTBP in Q4 2025 and held it in 2 quarters. The position peaked at $11.8K in Q4 2025. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

Cerity Partners reported no remaining GT Biopharma position as of Q2 2026 after selling out during the quarter.
Cerity Partners sold 801 GT Biopharma shares in Q2 2026, an estimated $8.17K.
Cerity Partners first reported a position in GT Biopharma in Q4 2025 and held it in 2 quarters.
Cerity Partners's GT Biopharma position peaked at $11.8K in Q4 2025.
55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.